首页 > 最新文献

American journal of clinical pathology最新文献

英文 中文
Correction to: Escalation process of critical values when these cannot be communicated on first attempt: A hospital-wide process improvement project. 更正:当关键值无法在首次尝试时传达时,升级关键值的流程:全院流程改进项目。
IF 2.3 4区 医学 Q2 PATHOLOGY Pub Date : 2024-11-19 DOI: 10.1093/ajcp/aqae157
{"title":"Correction to: Escalation process of critical values when these cannot be communicated on first attempt: A hospital-wide process improvement project.","authors":"","doi":"10.1093/ajcp/aqae157","DOIUrl":"https://doi.org/10.1093/ajcp/aqae157","url":null,"abstract":"","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142674883","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: Pilomatrix-like breast carcinoma: A mammary analog of pilomatrix-like high-grade endometrioid carcinoma (PiMHEC). 更正:皮瘤样乳腺癌:皮瘤样高级别子宫内膜样癌(PiMHEC)的乳腺类似物。
IF 2.3 4区 医学 Q2 PATHOLOGY Pub Date : 2024-11-14 DOI: 10.1093/ajcp/aqae154
{"title":"Correction to: Pilomatrix-like breast carcinoma: A mammary analog of pilomatrix-like high-grade endometrioid carcinoma (PiMHEC).","authors":"","doi":"10.1093/ajcp/aqae154","DOIUrl":"https://doi.org/10.1093/ajcp/aqae154","url":null,"abstract":"","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612151","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Survey of clinical microbiology and infectious disease testing capabilities among institutions in Africa. 非洲各机构临床微生物学和传染病检测能力调查。
IF 2.3 4区 医学 Q2 PATHOLOGY Pub Date : 2024-11-12 DOI: 10.1093/ajcp/aqae148
Jeremy W Jacobs, Brian D Adkins, Danny A Milner, Evan M Bloch, Quentin Eichbaum

Objectives: Inadequate laboratory infrastructure and testing capabilities are a major impediment to addressing the infectious disease burden in Africa. Therefore, the aims of this study were to characterize the clinical microbiology/infectious disease laboratory capabilities among countries in Africa.

Methods: A survey to assess the microbiological testing capabilities at hospitals, government laboratories, and free-standing public and private laboratories in African countries was developed by subject matter experts. Questions included institutional demographics and microbiology services in the broad categories of bacteriology, virology, mycology, parasitology, and rapid diagnostics/point-of-care testing. The survey was distributed using the American Society of Clinical Pathology email listserv between June and August 2022.

Results: In total, 131 unique institutions in 28 countries endorsed at least 1 type of microbiology service, with parasitology (80.9%, 106/131) and bacteriology (77.9%, 102/131) being most common, while mycology (45.0%, 59/131) and virology (45.8%, 60/131) laboratories were less prevalent. The most frequently performed bacteriology test was bacterial identification (90.2%, 92/102), followed by aerobic bacterial cultures and antimicrobial susceptibility testing (both 89.2%, 91/102). Among all clinical microbiology/infectious disease laboratories, the most commonly tested agents were HIV (90.8%, 119/131), Treponema pallidum (78.6%, 103/131), Plasmodium falciparum (76.3%, 100/131), Mycobacterium tuberculosis (76.3%, 100/131), and hepatitis C virus (74.8%, 98/131).

Conclusions: These findings provide contemporary data regarding the availability of critical infectious disease testing capabilities among institutions in Africa. These results and future additional studies will be crucial for understanding where strategic investment in the laboratory and public health infrastructure is warranted.

目标:实验室基础设施和检测能力不足是应对非洲传染病负担的主要障碍。因此,本研究旨在了解非洲各国临床微生物学/传染病实验室能力的特点:方法:主题专家制定了一项调查,以评估非洲国家的医院、政府实验室以及独立的公共和私营实验室的微生物检测能力。问题包括机构人口统计学和微生物学服务,大类包括细菌学、病毒学、真菌学、寄生虫学和快速诊断/护理点检测。调查在 2022 年 6 月至 8 月期间通过美国临床病理学会电子邮件列表服务进行分发:共有 28 个国家的 131 家机构认可至少一种微生物学服务,其中寄生虫学(80.9%,106/131)和细菌学(77.9%,102/131)最为常见,而真菌学(45.0%,59/131)和病毒学(45.8%,60/131)实验室较少。最常进行的细菌学检验是细菌鉴定(90.2%,92/102),其次是需氧细菌培养和抗菌药物药敏试验(均为 89.2%,91/102)。在所有临床微生物学/传染病实验室中,最常检测的病原体是艾滋病毒(90.8%,119/131)、苍白链球菌(78.6%,103/131)、恶性疟原虫(76.3%,100/131)、结核分枝杆菌(76.3%,100/131)和丙型肝炎病毒(74.8%,98/131):这些研究结果提供了有关非洲机构关键传染病检测能力可用性的最新数据。这些结果和未来的其他研究对于了解哪些领域需要对实验室和公共卫生基础设施进行战略投资至关重要。
{"title":"Survey of clinical microbiology and infectious disease testing capabilities among institutions in Africa.","authors":"Jeremy W Jacobs, Brian D Adkins, Danny A Milner, Evan M Bloch, Quentin Eichbaum","doi":"10.1093/ajcp/aqae148","DOIUrl":"https://doi.org/10.1093/ajcp/aqae148","url":null,"abstract":"<p><strong>Objectives: </strong>Inadequate laboratory infrastructure and testing capabilities are a major impediment to addressing the infectious disease burden in Africa. Therefore, the aims of this study were to characterize the clinical microbiology/infectious disease laboratory capabilities among countries in Africa.</p><p><strong>Methods: </strong>A survey to assess the microbiological testing capabilities at hospitals, government laboratories, and free-standing public and private laboratories in African countries was developed by subject matter experts. Questions included institutional demographics and microbiology services in the broad categories of bacteriology, virology, mycology, parasitology, and rapid diagnostics/point-of-care testing. The survey was distributed using the American Society of Clinical Pathology email listserv between June and August 2022.</p><p><strong>Results: </strong>In total, 131 unique institutions in 28 countries endorsed at least 1 type of microbiology service, with parasitology (80.9%, 106/131) and bacteriology (77.9%, 102/131) being most common, while mycology (45.0%, 59/131) and virology (45.8%, 60/131) laboratories were less prevalent. The most frequently performed bacteriology test was bacterial identification (90.2%, 92/102), followed by aerobic bacterial cultures and antimicrobial susceptibility testing (both 89.2%, 91/102). Among all clinical microbiology/infectious disease laboratories, the most commonly tested agents were HIV (90.8%, 119/131), Treponema pallidum (78.6%, 103/131), Plasmodium falciparum (76.3%, 100/131), Mycobacterium tuberculosis (76.3%, 100/131), and hepatitis C virus (74.8%, 98/131).</p><p><strong>Conclusions: </strong>These findings provide contemporary data regarding the availability of critical infectious disease testing capabilities among institutions in Africa. These results and future additional studies will be crucial for understanding where strategic investment in the laboratory and public health infrastructure is warranted.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612185","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Simplifying acquisition of essential diagnostics: A comprehensive costing tool for anatomic pathology. 简化基本诊断的获取:解剖病理学综合成本计算工具。
IF 2.3 4区 医学 Q2 PATHOLOGY Pub Date : 2024-11-11 DOI: 10.1093/ajcp/aqae138
Analise LeJeune-Stodieck, Daniel Seymour, Katy Graef, Elisee Hategekimana, Djibril Mbarushimana, Marie Claire Ndayisaba, Emilio Augusto Campos Pereira de Assis, Girogis Okubazgi Yeabyo, Michael Chukwugozium Nweke, Bereket Berhane, Hakizimana Emmanuel, Deo Ruhangaza, Callie Weber, Debby Basu, Kenneth Landgraf, Dan Milner

Objectives: Histopathology is the core diagnostic tool for cancer in pathology laboratories around the world, but there are disparities in access to diagnostics globally. As recognition of the need for cancer care and treatment grows, especially in the wake of World Health Organization programs for cervical, breast, and pediatric cancers, policymakers and health care funders are seeking tools and processes that allow for the largest number of patients to receive a diagnosis at the lowest cost.

Methods: As histopathology represents the most cost-effective diagnostic method by sheer number of tumor types and volume, understanding the detailed logistics and costs for histology as well as the impactful benefits of economies of scale (ie, larger volumes are less expensive per patient) and scope (ie, the multiple stains available after basic histology sectioning) is paramount to planning an effective publicly funded or government laboratory. Understanding the economic structure of a country's population along with the financial model of a histology laboratory also leads to a market understanding of private laboratories, which can provide services at a profit as well as pro bono services more cost-effectively than purely public laboratories.

Results: We have developed a comprehensive, scalable costing tool of a functioning histology laboratory that accounts for all feasible costs and variations in models of service. The tool allows for a standardized approach to selecting goods needed to provide histology services and serves as a guide for implementation of pathology services.

Conclusions: Using the tool, laboratories can achieve self-sustainment and long-term financial health while incorporating a proportion of impoverished patients who cannot afford out-of-pocket expenses.

目标:组织病理学是全世界病理实验室诊断癌症的核心工具,但在全球范围内,获得诊断的机会却存在差异。随着人们对癌症护理和治疗需求的认识与日俱增,尤其是世界卫生组织针对宫颈癌、乳腺癌和儿童癌症开展了相关计划之后,政策制定者和医疗保健资助者正在寻求能让最多患者以最低成本获得诊断的工具和流程:方法:组织病理学是最具成本效益的诊断方法,因为它涉及的肿瘤类型和数量众多,因此了解组织病理学的详细物流和成本,以及规模经济(即数量越大,每位患者的成本越低)和范围经济(即基本组织切片后可获得多种染色)的影响效益,对于规划一个有效的公共资助或政府实验室至关重要。了解一个国家人口的经济结构以及组织学实验室的财务模式,还可以了解私营实验室的市场情况,因为私营实验室可以提供盈利服务以及公益服务,比纯粹的公共实验室更具成本效益:我们开发了一个全面、可扩展的成本计算工具,用于计算一个正常运转的组织学实验室的所有可行成本和服务模式的变化。该工具允许采用标准化方法来选择提供组织学服务所需的物品,并可作为病理服务的实施指南:使用该工具,实验室可以实现自我维持和长期财务健康,同时将一部分无法负担自付费用的贫困患者纳入其中。
{"title":"Simplifying acquisition of essential diagnostics: A comprehensive costing tool for anatomic pathology.","authors":"Analise LeJeune-Stodieck, Daniel Seymour, Katy Graef, Elisee Hategekimana, Djibril Mbarushimana, Marie Claire Ndayisaba, Emilio Augusto Campos Pereira de Assis, Girogis Okubazgi Yeabyo, Michael Chukwugozium Nweke, Bereket Berhane, Hakizimana Emmanuel, Deo Ruhangaza, Callie Weber, Debby Basu, Kenneth Landgraf, Dan Milner","doi":"10.1093/ajcp/aqae138","DOIUrl":"https://doi.org/10.1093/ajcp/aqae138","url":null,"abstract":"<p><strong>Objectives: </strong>Histopathology is the core diagnostic tool for cancer in pathology laboratories around the world, but there are disparities in access to diagnostics globally. As recognition of the need for cancer care and treatment grows, especially in the wake of World Health Organization programs for cervical, breast, and pediatric cancers, policymakers and health care funders are seeking tools and processes that allow for the largest number of patients to receive a diagnosis at the lowest cost.</p><p><strong>Methods: </strong>As histopathology represents the most cost-effective diagnostic method by sheer number of tumor types and volume, understanding the detailed logistics and costs for histology as well as the impactful benefits of economies of scale (ie, larger volumes are less expensive per patient) and scope (ie, the multiple stains available after basic histology sectioning) is paramount to planning an effective publicly funded or government laboratory. Understanding the economic structure of a country's population along with the financial model of a histology laboratory also leads to a market understanding of private laboratories, which can provide services at a profit as well as pro bono services more cost-effectively than purely public laboratories.</p><p><strong>Results: </strong>We have developed a comprehensive, scalable costing tool of a functioning histology laboratory that accounts for all feasible costs and variations in models of service. The tool allows for a standardized approach to selecting goods needed to provide histology services and serves as a guide for implementation of pathology services.</p><p><strong>Conclusions: </strong>Using the tool, laboratories can achieve self-sustainment and long-term financial health while incorporating a proportion of impoverished patients who cannot afford out-of-pocket expenses.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Analytical performance of a point-of-care CBC hematology analyzer, including a 5-part differential: A prospective study to evaluate a microfluidic flow cytometry-based analyzer in waived settings. 护理点 CBC 血液分析仪的分析性能,包括 5 部分鉴别:一项前瞻性研究,评估基于微流体流式细胞仪的分析仪在免检环境中的应用。
IF 2.3 4区 医学 Q2 PATHOLOGY Pub Date : 2024-11-09 DOI: 10.1093/ajcp/aqae149
Jane F Emerson, Hao Wang, Imran N Siddiqi

Objectives: A microfluidic flow cytometer-based point-of-care (POC) analyzer was validated against an in-laboratory hematology analyzer (Sysmex XN Automated Hematology System). Concordance on a full complete blood cell count (CBC) with 5-part differential, as performed by operators with no prior clinical laboratory experience, was evaluated.

Methods: We prospectively collected 376 venous blood specimens (376) from individuals with self-reported medical conditions and from apparently healthy individuals. Forty-six additional remnant specimens were acquired to ensure coverage of analytic measuring ranges. Parallel testing was performed, with up to 7 hours between testing on the POC and Sysmex XN analyzers.

Results: Regression analysis resulted in r values of 0.998 to 0.932 for all parameters of a 5-part differential CBC other than basophils (0.709). The mean percentage bias from the reference method, inclusive of the upper and lower reporting limits, was less than 2% for parameters other than lymphocytes (-6.4%), monocytes (25.9%), eosinophils (12.2%), and basophils (-15%). Overall agreement on abnormal flagging was 93.3%.

Conclusions: The Cito CBC microflow cytometer (CytoChip Inc) provides a CBC with a 5-part differential with accuracy, precision, and abnormal flagging equivalent to a moderate-complexity hematology analyzer. It has the key features required of a POC device that can be operated in a waived setting: minimum space requirements, rapid results, single-action measurement (no sample processing or dilution), ease of use, and minimal blood volume.

目标:将基于微流体流式细胞仪的护理点(POC)分析仪与实验室血液分析仪(Sysmex XN 自动血液分析系统)进行对比验证。方法:我们前瞻性地收集了 376 份静脉血样本,并对这些样本进行了分析:我们前瞻性地收集了 376 份静脉血标本(376 份),这些标本分别来自自述患有疾病的人和表面健康的人。另外还采集了 46 份残留标本,以确保覆盖分析测量范围。在 POC 分析仪和 Sysmex XN 分析仪上进行了平行测试,测试间隔时间长达 7 小时:结果:回归分析结果显示,除嗜碱性粒细胞(0.709)外,5 部分差异 CBC 所有参数的 r 值均为 0.998 至 0.932。除淋巴细胞(-6.4%)、单核细胞(25.9%)、嗜酸性粒细胞(12.2%)和嗜碱性粒细胞(-15%)外,其他参数与参考方法的平均偏差百分比(包括报告上下限)均小于 2%。异常标记的总体一致性为 93.3%:Cito CBC 微流式细胞仪(CytoChip Inc)可提供具有 5 部分鉴别功能的 CBC,其准确性、精确性和异常标记功能与中等复杂程度的血液分析仪相当。它具有可在免检环境下操作的 POC 设备所需的关键特性:最小空间要求、快速结果、单次测量(无需样本处理或稀释)、易于使用和最小血容量。
{"title":"Analytical performance of a point-of-care CBC hematology analyzer, including a 5-part differential: A prospective study to evaluate a microfluidic flow cytometry-based analyzer in waived settings.","authors":"Jane F Emerson, Hao Wang, Imran N Siddiqi","doi":"10.1093/ajcp/aqae149","DOIUrl":"https://doi.org/10.1093/ajcp/aqae149","url":null,"abstract":"<p><strong>Objectives: </strong>A microfluidic flow cytometer-based point-of-care (POC) analyzer was validated against an in-laboratory hematology analyzer (Sysmex XN Automated Hematology System). Concordance on a full complete blood cell count (CBC) with 5-part differential, as performed by operators with no prior clinical laboratory experience, was evaluated.</p><p><strong>Methods: </strong>We prospectively collected 376 venous blood specimens (376) from individuals with self-reported medical conditions and from apparently healthy individuals. Forty-six additional remnant specimens were acquired to ensure coverage of analytic measuring ranges. Parallel testing was performed, with up to 7 hours between testing on the POC and Sysmex XN analyzers.</p><p><strong>Results: </strong>Regression analysis resulted in r values of 0.998 to 0.932 for all parameters of a 5-part differential CBC other than basophils (0.709). The mean percentage bias from the reference method, inclusive of the upper and lower reporting limits, was less than 2% for parameters other than lymphocytes (-6.4%), monocytes (25.9%), eosinophils (12.2%), and basophils (-15%). Overall agreement on abnormal flagging was 93.3%.</p><p><strong>Conclusions: </strong>The Cito CBC microflow cytometer (CytoChip Inc) provides a CBC with a 5-part differential with accuracy, precision, and abnormal flagging equivalent to a moderate-complexity hematology analyzer. It has the key features required of a POC device that can be operated in a waived setting: minimum space requirements, rapid results, single-action measurement (no sample processing or dilution), ease of use, and minimal blood volume.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612147","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Factors impacting tumor displacement artifact and pseudo-lymphovascular invasion in testicular germ cell tumors. 影响睾丸生殖细胞瘤肿瘤移位假象和假淋巴管侵犯的因素
IF 2.3 4区 医学 Q2 PATHOLOGY Pub Date : 2024-11-09 DOI: 10.1093/ajcp/aqae147
Reem O Ahmed, Debra L Zynger

Objectives: Testicular germ cell tumors are susceptible to tumor displacement artifact (TDA), which produces pseudo-lymphovascular invasion (LVI) and confounds the identification of true LVI. Our study aimed to evaluate tumor displacement artifact and pseudo-LVI in testicular germ cell tumors and determine if prolonged fixation improves histological quality.

Methods: A retrospective search identified 121 orchiectomies with slides that were reviewed to assess TDA and pseudo-LVI.

Results: Seminoma had more TDA (68% vs 45%, P = .01) and pseudo-LVI (53% vs 19%, P < .001) than mixed germ cell tumor. Seminoma and mixed germ cell tumor with TDA and pseudo-LVI were larger than those without. Mixed germ cell tumor with ≥50% composition of seminoma had a higher rate of TDA (89% vs 38%, P = .008) and pseudo-LVI (44% vs 15%, P = .06) than those with less. TDA was reduced in seminoma with >1 night fixation compared to no fixation (50% vs 82%, P = .046), with a similar trend in mixed germ cell tumor (31% vs 60%, P = .15). A trend in reduction of pseudo-LVI was seen with >1 night fixation compared to no fixation in seminoma (64% vs 39%, P = .12).

Conclusions: Seminomas and larger germ cell tumors were more prone to TDA and pseudo-LVI. Prolonged formalin fixation improved histological quality in testicular germ cell tumors. Based on these data, we recommend fixation for at least 2 nights before sectioning orchiectomy specimens, particularly for larger tumors.

目的:睾丸生殖细胞肿瘤易受肿瘤移位伪影(TDA)的影响,TDA会产生假性淋巴管侵犯(LVI),混淆真性LVI的鉴定。我们的研究旨在评估睾丸生殖细胞肿瘤中的肿瘤移位伪影和假性LVI,并确定延长固定时间是否能提高组织学质量:方法:通过回顾性检索确定了121例睾丸切除术,并对切片进行了审查,以评估TDA和假性LVI:结果:与混合生殖细胞瘤相比,精原细胞瘤有更多的TDA(68% vs 45%,P = .01)和假性LVI(53% vs 19%,P < .001)。有TDA和假性LVI的精原细胞瘤和混合生殖细胞瘤比没有TDA和假性LVI的要大。精原细胞瘤成分≥50%的混合生殖细胞瘤的TDA(89% vs 38%,P = .008)和假性LVI(44% vs 15%,P = .06)率高于成分较少的混合生殖细胞瘤。精原细胞瘤固定时间大于 1 晚的 TDA 比未固定的要低(50% vs 82%,P = .046),混合生殖细胞瘤也有类似趋势(31% vs 60%,P = .15)。在精原细胞瘤中,与不固定相比,固定>1晚后假性LVI有下降趋势(64% vs 39%,P = .12):结论:精原细胞瘤和较大的生殖细胞瘤更容易发生TDA和假性LVI。结论:精原细胞瘤和较大的生殖细胞瘤更容易发生 TDA 和假性 LVI,长期福尔马林固定可改善睾丸生殖细胞瘤的组织学质量。基于这些数据,我们建议在睾丸切除术标本切片前至少固定两晚,尤其是较大的肿瘤。
{"title":"Factors impacting tumor displacement artifact and pseudo-lymphovascular invasion in testicular germ cell tumors.","authors":"Reem O Ahmed, Debra L Zynger","doi":"10.1093/ajcp/aqae147","DOIUrl":"https://doi.org/10.1093/ajcp/aqae147","url":null,"abstract":"<p><strong>Objectives: </strong>Testicular germ cell tumors are susceptible to tumor displacement artifact (TDA), which produces pseudo-lymphovascular invasion (LVI) and confounds the identification of true LVI. Our study aimed to evaluate tumor displacement artifact and pseudo-LVI in testicular germ cell tumors and determine if prolonged fixation improves histological quality.</p><p><strong>Methods: </strong>A retrospective search identified 121 orchiectomies with slides that were reviewed to assess TDA and pseudo-LVI.</p><p><strong>Results: </strong>Seminoma had more TDA (68% vs 45%, P = .01) and pseudo-LVI (53% vs 19%, P < .001) than mixed germ cell tumor. Seminoma and mixed germ cell tumor with TDA and pseudo-LVI were larger than those without. Mixed germ cell tumor with ≥50% composition of seminoma had a higher rate of TDA (89% vs 38%, P = .008) and pseudo-LVI (44% vs 15%, P = .06) than those with less. TDA was reduced in seminoma with >1 night fixation compared to no fixation (50% vs 82%, P = .046), with a similar trend in mixed germ cell tumor (31% vs 60%, P = .15). A trend in reduction of pseudo-LVI was seen with >1 night fixation compared to no fixation in seminoma (64% vs 39%, P = .12).</p><p><strong>Conclusions: </strong>Seminomas and larger germ cell tumors were more prone to TDA and pseudo-LVI. Prolonged formalin fixation improved histological quality in testicular germ cell tumors. Based on these data, we recommend fixation for at least 2 nights before sectioning orchiectomy specimens, particularly for larger tumors.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142612170","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Correction to: The American Society for Clinical Pathology's 2023 wage survey of medical laboratories in the United States. 更正:美国临床病理学会 2023 年美国医学实验室工资调查。
IF 2.3 4区 医学 Q2 PATHOLOGY Pub Date : 2024-11-08 DOI: 10.1093/ajcp/aqae152
{"title":"Correction to: The American Society for Clinical Pathology's 2023 wage survey of medical laboratories in the United States.","authors":"","doi":"10.1093/ajcp/aqae152","DOIUrl":"https://doi.org/10.1093/ajcp/aqae152","url":null,"abstract":"","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":""},"PeriodicalIF":2.3,"publicationDate":"2024-11-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142602632","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement. 带有 CBFB 重排的急性髓性白血病的免疫表型和遗传特征综合分析。
IF 2.3 4区 医学 Q2 PATHOLOGY Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae060
Fnu Sameeta, Sa A Wang, Zhenya Tang, Joseph D Khoury, Hong Fang, Dylan Wang, Jie Xu, Shaoying Li, Zhihong Hu, Shimin Hu, Jeffrey L Jorgensen, L Jeffrey Medeiros, Wei Wang

Objectives: We sought to characterize the immunophenotype of acute myeloid leukemia (AML) with CBFB rearrangement and correlate the results with cytogenetic and molecular data.

Methods: Sixty-one cases of AML with CBFB rearrangement were evaluated.

Results: The sample population consisted of 33 men and 28 women, with a median age of 49 years. Flow cytometry immunophenotypic analysis showed that myeloblasts were positive for CD34 and CD117 in all cases, and myeloperoxidase was positive in 52 of 55 (95%) cases. The most common abnormalities included decreased CD38 in 90%, increased CD13 in 85%, increased CD123 in 84%, and decreased HLA-DR in 84% of cases. Monocytes were increased, with a mature immunophenotype, and accounted for 23.7% of total cells. Among 60 cases with available karyotype, inv(16)(p13.1q22) was most common in 50 (83%) cases, followed by t(16;16) (p13.1;q22) in 6 (10%). Type A CBFB::MYH11 transcript was most common, detected in 84% of cases. Mutational analysis showed mutations of NRAS in 37%, FLT3 in 25%, and KIT in 24% of cases. Comparing cases with type A vs non-type A transcripts, blasts in type A cases more frequently exhibited CD64 positivity and increased CD13 levels while showing a lower frequency of CD7 and CD56 expression. Trisomy 22 and mutations in KIT, NF1, and TET2 were identified only in cases with type A transcript.

Conclusions: Myeloblasts of AML with CBFB rearrangement are positive for CD34, CD117, and myeloperoxidase. These neoplasms most frequently carry inv(16)(p13.1q22) and type A fusion transcript. NRAS mutation was the most common mutation. Some immunophenotypic and genetic correlations occurred with different types of transcripts.

目的:我们试图描述伴有CBFB重排的急性髓性白血病(AML)的免疫表型,并将结果与细胞遗传学和分子数据进行关联:我们试图描述伴有CBFB重排的急性髓性白血病(AML)的免疫表型特征,并将结果与细胞遗传学和分子数据相关联:方法:对61例CBFB重排的急性髓性白血病病例进行了评估:结果:样本人群包括 33 名男性和 28 名女性,中位年龄为 49 岁。流式细胞术免疫表型分析显示,所有病例的骨髓细胞 CD34 和 CD117 均呈阳性,55 例病例中有 52 例(95%)骨髓过氧化物酶呈阳性。最常见的异常包括 90% 的病例中 CD38 减少,85% 的病例中 CD13 增加,84% 的病例中 CD123 增加,84% 的病例中 HLA-DR 减少。单核细胞增多,免疫表型成熟,占细胞总数的 23.7%。在 60 例可提供核型的病例中,inv(16)(p13.1q22) 最常见,占 50 例(83%),其次是 t(16;16) (p13.1;q22),占 6 例(10%)。A型CBFB::MYH11转录本最常见,在84%的病例中检测到。突变分析显示,37%的病例存在NRAS突变,25%的病例存在FLT3突变,24%的病例存在KIT突变。比较A型与非A型转录本的病例,A型病例的胚泡更常表现出CD64阳性和CD13水平升高,而CD7和CD56的表达频率较低。只有在A型转录本病例中才发现了22三体综合征以及KIT、NF1和TET2突变:结论:具有 CBFB 重排的急性髓细胞性白血病骨髓母细胞的 CD34、CD117 和髓过氧化物酶均呈阳性。这些肿瘤最常携带 inv(16)(p13.1q22) 和 A 型融合转录本。NRAS突变是最常见的突变。不同类型的转录本存在一些免疫表型和遗传相关性。
{"title":"Integrative immunophenotypic and genetic characterization of acute myeloid leukemia with CBFB rearrangement.","authors":"Fnu Sameeta, Sa A Wang, Zhenya Tang, Joseph D Khoury, Hong Fang, Dylan Wang, Jie Xu, Shaoying Li, Zhihong Hu, Shimin Hu, Jeffrey L Jorgensen, L Jeffrey Medeiros, Wei Wang","doi":"10.1093/ajcp/aqae060","DOIUrl":"10.1093/ajcp/aqae060","url":null,"abstract":"<p><strong>Objectives: </strong>We sought to characterize the immunophenotype of acute myeloid leukemia (AML) with CBFB rearrangement and correlate the results with cytogenetic and molecular data.</p><p><strong>Methods: </strong>Sixty-one cases of AML with CBFB rearrangement were evaluated.</p><p><strong>Results: </strong>The sample population consisted of 33 men and 28 women, with a median age of 49 years. Flow cytometry immunophenotypic analysis showed that myeloblasts were positive for CD34 and CD117 in all cases, and myeloperoxidase was positive in 52 of 55 (95%) cases. The most common abnormalities included decreased CD38 in 90%, increased CD13 in 85%, increased CD123 in 84%, and decreased HLA-DR in 84% of cases. Monocytes were increased, with a mature immunophenotype, and accounted for 23.7% of total cells. Among 60 cases with available karyotype, inv(16)(p13.1q22) was most common in 50 (83%) cases, followed by t(16;16) (p13.1;q22) in 6 (10%). Type A CBFB::MYH11 transcript was most common, detected in 84% of cases. Mutational analysis showed mutations of NRAS in 37%, FLT3 in 25%, and KIT in 24% of cases. Comparing cases with type A vs non-type A transcripts, blasts in type A cases more frequently exhibited CD64 positivity and increased CD13 levels while showing a lower frequency of CD7 and CD56 expression. Trisomy 22 and mutations in KIT, NF1, and TET2 were identified only in cases with type A transcript.</p><p><strong>Conclusions: </strong>Myeloblasts of AML with CBFB rearrangement are positive for CD34, CD117, and myeloperoxidase. These neoplasms most frequently carry inv(16)(p13.1q22) and type A fusion transcript. NRAS mutation was the most common mutation. Some immunophenotypic and genetic correlations occurred with different types of transcripts.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"455-463"},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141154551","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diagnostic accuracy of upper tract urothelial carcinoma using biopsy, urinary cytology, and nephroureterectomy specimens: A tertiary cancer center experience. 利用活组织检查、尿液细胞学检查和肾切除术标本诊断上尿路上皮癌的准确性:一家三级癌症中心的经验。
IF 2.3 4区 医学 Q2 PATHOLOGY Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae065
Jianping Zhao, Yuan Shen, Ming Guo, Surena F Matin, Donna E Hansel, Charles C Guo

Objectives: We studied the diagnostic accuracy and discordance of upper tract urothelial carcinoma (UTUC) by comparing biopsy and urinary cytology with matched nephroureterectomy specimens.

Methods: Sixty-nine patients with UTUC without neoadjuvant treatment were retrospectively identified who had matched biopsy and nephroureterectomy specimens. Twenty patients had concurrent upper tract cytology. H&E and cytology slides were re-reviewed. Statistical analysis was performed.

Results: Patients included 48 men and 21 women with a mean age of 69 years. A concordant grade between biopsy and surgical specimen was present in 49 (71%) patients. The mean size of biopsy specimens in the discordant group was significantly smaller than that in the concordant group. Invasion was evaluated in 48 biopsy cases that had adequate subepithelial tissue, and 33 of them were diagnosed with concordant invasion status. Mean tumor size in both tumor grade and invasion discordant groups was significantly larger than that in the concordant group. High-grade urothelial carcinoma was detected in 84% of cases using urinary cytology.

Conclusions: Our study demonstrates the diagnostic challenges of UTUC on small biopsy specimens. Biopsy specimen size and tumor size are significantly associated with the diagnostic discordance. Upper tract cytology showed high diagnostic accuracy and should be complementary to the biopsy.

目的:我们通过比较活组织检查和尿液细胞学检查与匹配的肾切除术标本,研究了上尿路尿路上皮癌(UTUC)的诊断准确性和不一致性:回顾性研究确定了69例未经新辅助治疗的UTUC患者,这些患者的活检和肾切除术标本相匹配。20名患者同时进行了上道细胞学检查。对H&E和细胞学切片进行了重新审查。进行统计分析:患者包括 48 名男性和 21 名女性,平均年龄为 69 岁。49例(71%)患者的活检和手术标本的分级一致。不一致组活检标本的平均尺寸明显小于一致组。对 48 例有足够上皮下组织的活检样本进行了浸润评估,其中 33 例被诊断为浸润状态一致。肿瘤分级和浸润不一致组的平均肿瘤大小明显大于一致组。84%的病例通过尿液细胞学检查发现了高级别尿路上皮癌:结论:我们的研究表明,小活检标本对UTUC的诊断具有挑战性。活检标本大小和肿瘤大小与诊断不一致有很大关系。上尿路细胞学诊断准确率较高,应作为活检的补充。
{"title":"Diagnostic accuracy of upper tract urothelial carcinoma using biopsy, urinary cytology, and nephroureterectomy specimens: A tertiary cancer center experience.","authors":"Jianping Zhao, Yuan Shen, Ming Guo, Surena F Matin, Donna E Hansel, Charles C Guo","doi":"10.1093/ajcp/aqae065","DOIUrl":"10.1093/ajcp/aqae065","url":null,"abstract":"<p><strong>Objectives: </strong>We studied the diagnostic accuracy and discordance of upper tract urothelial carcinoma (UTUC) by comparing biopsy and urinary cytology with matched nephroureterectomy specimens.</p><p><strong>Methods: </strong>Sixty-nine patients with UTUC without neoadjuvant treatment were retrospectively identified who had matched biopsy and nephroureterectomy specimens. Twenty patients had concurrent upper tract cytology. H&E and cytology slides were re-reviewed. Statistical analysis was performed.</p><p><strong>Results: </strong>Patients included 48 men and 21 women with a mean age of 69 years. A concordant grade between biopsy and surgical specimen was present in 49 (71%) patients. The mean size of biopsy specimens in the discordant group was significantly smaller than that in the concordant group. Invasion was evaluated in 48 biopsy cases that had adequate subepithelial tissue, and 33 of them were diagnosed with concordant invasion status. Mean tumor size in both tumor grade and invasion discordant groups was significantly larger than that in the concordant group. High-grade urothelial carcinoma was detected in 84% of cases using urinary cytology.</p><p><strong>Conclusions: </strong>Our study demonstrates the diagnostic challenges of UTUC on small biopsy specimens. Biopsy specimen size and tumor size are significantly associated with the diagnostic discordance. Upper tract cytology showed high diagnostic accuracy and should be complementary to the biopsy.</p>","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"492-499"},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141299707","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Reply to "Performance of GPT-4 Vision on kidney pathology exam questions". 答复 "GPT-4 Vision 在肾脏病理学试题中的表现"。
IF 2.3 4区 医学 Q2 PATHOLOGY Pub Date : 2024-11-04 DOI: 10.1093/ajcp/aqae059
Jing Miao, Charat Thongprayoon, Wisit Cheungpasitporn, Lynn D Cornell
{"title":"Reply to \"Performance of GPT-4 Vision on kidney pathology exam questions\".","authors":"Jing Miao, Charat Thongprayoon, Wisit Cheungpasitporn, Lynn D Cornell","doi":"10.1093/ajcp/aqae059","DOIUrl":"10.1093/ajcp/aqae059","url":null,"abstract":"","PeriodicalId":7506,"journal":{"name":"American journal of clinical pathology","volume":" ","pages":"536"},"PeriodicalIF":2.3,"publicationDate":"2024-11-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"141064842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
American journal of clinical pathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1